Clinical trials
Completed Hepatitis B, Chronic trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
389 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 5 |
| 2002 | 8 |
| 2003 | 10 |
| 2004 | 12 |
| 2005 | 17 |
| 2006 | 15 |
| 2007 | 20 |
| 2008 | 21 |
| 2009 | 24 |
| 2010 | 18 |
| 2011 | 20 |
| 2012 | 19 |
| 2013 | 13 |
| 2014 | 16 |
| 2015 | 19 |
| 2016 | 13 |
| 2017 | 18 |
| 2018 | 21 |
| 2019 | 11 |
| 2020 | 20 |
| 2021 | 18 |
| 2022 | 19 |
| 2023 | 13 |
| 2024 | 8 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 389 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 38 |
| Gilead Sciences | 28 |
| GlaxoSmithKline | 24 |
| Bristol-Myers Squibb | 22 |
| Assembly Biosciences | 12 |
| Novartis Pharmaceuticals | 11 |
| Foundation for Liver Research | 7 |
| The University of Hong Kong | 7 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 6 |
| Bukwang Pharmaceutical | 5 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hepatitis B, Chronic | 389 |
| Hepatitis B | 71 |
| Hepatitis | 18 |
| Liver Cirrhosis | 11 |
| Fibrosis | 10 |
| Hepatitis, Chronic | 7 |
| Carcinoma, Hepatocellular | 6 |
| Fatty Liver | 5 |
| DNA Virus Infections | 4 |
| Liver Diseases | 4 |
Trials
Showing 1 to 25 of 389. Each trial links to its page on Pharma Observatory.
289 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.